Baird Financial Group Inc. Sells 1,135 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Baird Financial Group Inc. decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,713 shares of the biopharmaceutical company's stock after selling 1,135 shares during the period. Baird Financial Group Inc.'s holdings in Regeneron Pharmaceuticals were worth $24,727,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of REGN. Principal Financial Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after purchasing an additional 2,828 shares in the last quarter. Nordea Investment Management AB grew its holdings in Regeneron Pharmaceuticals by 23.6% during the fourth quarter. Nordea Investment Management AB now owns 42,667 shares of the biopharmaceutical company's stock valued at $30,160,000 after purchasing an additional 8,135 shares during the period. Diversified Trust Co increased its position in shares of Regeneron Pharmaceuticals by 93.0% in the 4th quarter. Diversified Trust Co now owns 2,330 shares of the biopharmaceutical company's stock valued at $1,660,000 after buying an additional 1,123 shares in the last quarter. Range Financial Group LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $220,000. Finally, First Hawaiian Bank increased its position in shares of Regeneron Pharmaceuticals by 18.8% during the fourth quarter. First Hawaiian Bank now owns 2,995 shares of the biopharmaceutical company's stock worth $2,133,000 after acquiring an additional 474 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded down $19.89 during midday trading on Friday, hitting $527.78. The company had a trading volume of 1,498,740 shares, compared to its average volume of 769,971. The company has a market capitalization of $57.70 billion, a PE ratio of 13.79, a P/E/G ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 52-week low of $520.50 and a 52-week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock's fifty day moving average price is $613.08 and its 200-day moving average price is $695.07.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the prior year, the business posted $9.55 EPS. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.67%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Bernstein Bank lowered their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Royal Bank of Canada decreased their price objective on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Finally, UBS Group reduced their target price on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $892.60.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.